TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02914275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seqirus Quadrivalent Inactivated Influenza Vaccine
Description: The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seqirus Quadrivalent Inactivated Influenza Vaccine
Description: The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Quadrivalent Inactivated Influenza Vaccine
Description: The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection of the non-dominant arm in children 36 months through 59 months of age.
Study: NCT01135615

Intervention type: DRUG
Group type: OTHER
Intervention: calcium acetate
Description: calcium acetate (1000 mg) 1 tablet three times a day

Intervention type: DRUG
Group type: OTHER
Intervention: calcium acetate
Description: calcium acetate (1000 mg) 1 tablet three times a day
Study: NCT02660853

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FEV1
Description: Participants have FEV1 test
Study: NCT04484870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Danshu capsule
Description: Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
Study: NCT02914275

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Quadrivalent Inactivated Influenza Vaccine
Description: The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection of the non-dominant arm in children 36 months through 59 months of age.
Study: NCT04334200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultivate yourself: support for caregivers of dementia persons
Description: The Chinese cultural values, including philosophical thoughts, will be included in the intervention. Chinese philosophical thoughts including the concepts of moderation, improving oneself, and harmony with nature will be used in the intervention. Confucianism, Taoism and Buddhism are the foundation for Chinese for concepts of health and illness, health promotion, and health-seeking behavior. Therefore, it is necessary to incorporate such philosophies in the sessions of the program.
Study: NCT04484870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral Danshu capsule
Description: Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
Study: NCT01360320

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea extract of Camellia Sinensis
Description: Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks~* 150mg EGCG two times daily (p.o.) over the course of three years.~* Colonoscopy after 3 years

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green tea extract of Camellia Sinensis followed by placebo
Description: Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks~* Placebo two times daily (p.o.) over the course of three years~* Colonoscopy after 3 years
Study: NCT02426463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Study: NCT04380389

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: hypoxia
Description: Brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained.
Study: NCT01290757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150 mg Capsugel (T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150 mg Qualicaps (R)
Study: NCT01433016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C Sodium Octanoate
Description: 13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
Study: NCT03487991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized sleep intervention
Description: Personalized feedback and recommendations based on study observations of sleep behavior and how participants cope with potentially sleep disruptive cognitions on their frequency and impact and on sleep efficiency. A written report is provided to participants and their initial modifications are monitored.
Study: NCT03468244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized mRNA Tumor Vaccine
Description: subcutaneous injection with personalized mRNA tumor vaccine at least four times
Study: NCT02719613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Study: NCT00202761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIH
Description: Intensified training
Study: NCT01544725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procedural sedation with ketamine-propofol combination
Description: K= Kétamine P= Propofol RSS= Ramsay Sedation Score~At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).~At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procedural sedation with ketamine alone
Description: K= Ketamine I= Intralipid placebo~At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).~At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver).
Study: NCT00350571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief (behavioral therapy)
Description: up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drop out re-engagement motivational intervention
Description: Up to 3 phone or office based counseling sessions to promote reengagement in treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care follow up
Description: routine counselor phone calls and letters
Study: NCT03214861

Intervention type: OTHER
Intervention: Carbohydrate quality
Description: This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.

Intervention type: OTHER
Intervention: Carbohydrate quality
Description: This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.
Study: NCT00687687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSI-201 (Iniparib)
Description: BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
Study: NCT01203735

Intervention type: DRUG
Group type: OTHER
Intervention: Valproic acid
Description: 800mg per day for entire period of RT
Study: NCT01744249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Description: Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sandostatin LAR
Description: Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
Study: NCT02334982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-137 placebo-matching tablets
Study: NCT02814084

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Internal Mammary Artery grafts
Description: Sternal Wound Edge Oxygenation in patients undergoing Coronary Artery bypass surgery with Bilateral Internal Mammary Artery grafts

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: The Prevena wound management system applies negative pressure to the closed wound for up to 7 days and is associated with lower rates of surgical site infection.
Study: NCT04565093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iPACK
Description: Interspace between the popliteal artery and the capsule of the posterior knee (iPACK):~This is basically ultrasound guided peripheral nerve block performed by the anesthesiologists at the posterior side of the knee to control pain after TKA.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periarticular local infiltration analgesia (LIA)
Description: A mixture of Bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This intervention is commonly performed by the operating orthopedic surgeon to control pain after TKA.
Study: NCT04341402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antifungal Nail Gel Study
Description: Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.
Study: NCT04242836

Intervention type: DIAGNOSTIC_TEST
Intervention: MNREAD testing
Description: One randomly selected eye is included for each study participant. Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.

Intervention type: DIAGNOSTIC_TEST
Intervention: MNREAD testing
Description: One randomly selected eye is included for each study participant. Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
Study: NCT04135690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400mg bid po

Intervention type: DRUG
Group type: OTHER
Intervention: systemic treatment
Description: atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on
Study: NCT03712904

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo radiation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study: NCT00909337

Intervention type: DRUG
Group type: OTHER
Intervention: Bosentan
Description: 2x62.5mg for 4 weeks, then 2x125mg
Study: NCT02576639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to CNP520 was supplied in capsules.
Study: NCT02289677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATMOS Scope
Description: Video-laryngoscopy 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COOPDECH
Description: Video-laryngoscopy-1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: Optical-laryngoscopy
Study: NCT00564460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride 5 mg PO once daily for 8 weeks prior to TURP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 8 weeks
Study: NCT04585854

Intervention type: OTHER
Group type: OTHER
Intervention: Caffeine
Description: Consumption of 3 shots of espresso
Study: NCT01877512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Change in daily dosage of Growth Hormone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Change in daily dosage of Growth Hormone
Study: NCT04236102

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples
Description: Automated real time PCR mutation analysis - 1. Can the Idylla platform provide a standardised and effective method for detecting EGFR, KRAS and BRAF mutations in blood and liquid based cytology samples for patients with lung and pancreatic cancer. Mutation detection increases the treatment options for patients.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples
Description: Automated real time PCR mutation analysis - 1. Can the Idylla platform provide a standardised and effective method for detecting EGFR, KRAS and BRAF mutations in blood and liquid based cytology samples for patients with lung and pancreatic cancer. Mutation detection increases the treatment options for patients.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples
Description: Automated real time PCR mutation analysis - 1. Can the Idylla platform provide a standardised and effective method for detecting EGFR, KRAS and BRAF mutations in blood and liquid based cytology samples for patients with lung and pancreatic cancer. Mutation detection increases the treatment options for patients.
Study: NCT01730521

Intervention type: BEHAVIORAL
Intervention: Exercise (Running)
Description: the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
Study: NCT03679065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
Study: NCT04504981

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Y2Prevent
Description: Y2Prevent (Y2P) is a groupl level intervention that consists of 7 weekly group sessions focused on helping young African American men who have sex with men (AAYMSM) identify life goals and safeguard their health to achieve those goals
Study: NCT02394535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy